Optimization of Minocycline-containing Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: a Multicentre, Randomized Controlled Trial

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The efficacy of bismuth-containing quadruple therapy with minocycline and metronidazole was not inferior to classical bismuth quadruple therapy for refractory H. pylori infection, though also accompanied with high occurrence of adverse events (55.4%). Optimization of minocycline-based regimen to achieve high eradication rate with fewer adverse events is imperative. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy with different dosage of minocycline and metronidazole compared to classical bismuth quadruple therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Ability and willingness to participate in the study and to sign and give informed consent

• Confirmed H. pylori infection and with previous treatment experience

Locations
Other Locations
China
Peking University Third Hospital
RECRUITING
Beijing
The Second Affiliated Hospital of Zhejiang University school of Medicine
RECRUITING
Hangzhou
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITING
Shanghai
Songjiang Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITING
Shanghai
Time Frame
Start Date: 2024-08-21
Estimated Completion Date: 2026-08-30
Participants
Target number of participants: 476
Treatments
Experimental: Minocycline group A
Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg tid, Metronidazole 400mg tid
Experimental: Minocycline group B
Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg bid, Metronidazole 400mg qid
Experimental: Minocycline group C
Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Minocycline 50mg bid, Metronidazole 400mg tid
Active_comparator: Tetracycline group
Vonoprazan 20mg bid, Bismuth Potassium Citrate 300mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
Related Therapeutic Areas
Sponsors
Leads: Shanghai Jiao Tong University School of Medicine

This content was sourced from clinicaltrials.gov

Similar Clinical Trials